Bicalutamide in advanced prostate cancer: A review
KL Goa, CM Spencer - Drugs & aging, 1998 - Springer
Synopsis Bicalutamide is a nonsteroidal antiandrogen with a long elimination half-life (t½)
that permits once-daily administration. When combined with a gonadorelin (gonadotrophin …
that permits once-daily administration. When combined with a gonadorelin (gonadotrophin …
Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy …
H Akaza, A Yamaguchi, T Matsuda… - Japanese journal of …, 2004 - academic.oup.com
Abstract Objectives: To evaluate bicalutamide (Casodex) 80 mg as a component of
maximum androgen blockade (MAB) in Japanese patients with previously untreated …
maximum androgen blockade (MAB) in Japanese patients with previously untreated …
Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity
G Kolvenbag, BJA Furr, GRP Blackledge - Prostate cancer and prostatic …, 1998 - nature.com
The non-steroidal antiandrogens flutamide (Eulexin®), nilutamide (Anandron®) and
bicalutamide (Casodex®) are widely used in the treatment of advanced prostate cancer …
bicalutamide (Casodex®) are widely used in the treatment of advanced prostate cancer …
Skeletal Muscle Function Is Altered in Male Mice on Low-Dose Androgen Receptor Antagonist or Estrogen Receptor Agonist
BA Momb, GK Szabo, JP Mogus, SR Chipkin… - …, 2023 - academic.oup.com
In males, skeletal muscle function may be altered by shifts in either circulating testosterone
or estrogen. We examined the effect of acute (2-week) exposures to 17α-ethinyl estradiol …
or estrogen. We examined the effect of acute (2-week) exposures to 17α-ethinyl estradiol …
Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a …
H Akaza, Y Homma, K Okada… - Japanese Journal of …, 2000 - academic.oup.com
Background: The majority of patients with localized and some cases of locally advanced
prostate cancer undergo radical prostatectomy. However, radical prostatectomy cannot …
prostate cancer undergo radical prostatectomy. However, radical prostatectomy cannot …
Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone …
K Gotanda, A Shinbo, M Okada, Y Nakano… - Prostate Cancer and …, 2003 - nature.com
We investigated whether the combination of chlormadinone acetate (CMA) and a luteinizing
hormone releasing hormone (LH-RH) agonist, leuprorelin acetate (leuprorelin), more …
hormone releasing hormone (LH-RH) agonist, leuprorelin acetate (leuprorelin), more …
Hormonal Therapy: Neoadjuvant, Adjuvant, Definitive, and Intermittent
A Ziada, M Rosenblum, ED Crawford - Management of Prostate Cancer, 2000 - Springer
The earliest references of the interaction between hormones and prostate were described in
the latter part of the 19th century, almost 50 yr before the description of testosterone and its …
the latter part of the 19th century, almost 50 yr before the description of testosterone and its …
前立腺癌患者に対するフルタミド投与前後の肝機能の検討LHRH アナログ併用例での検討
池本庸， 大石幸彦， 山崎春城， 和田鉄郎… - 日本泌尿器科学会 …, 2000 - jstage.jst.go.jp
前立腺癌患者 に対するフルタミド投与前後の肝機能の検討 LHRHア ナログ併用例での検討一
Page 1 日泌 尿 会 誌, 91巻, 6号, 2000年: 556~561 前立腺癌患者 に対するフルタミド投与前後の …
Page 1 日泌 尿 会 誌, 91巻, 6号, 2000年: 556~561 前立腺癌患者 に対するフルタミド投与前後の …